• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Government Agencies / North American / The United States / FDA / FDA: Infants May Get Meningococcal Vaccine

FDA: Infants May Get Meningococcal Vaccine

April 24, 2011 By Norma Leave a Comment

By Joyce Frieden, News Editor, MedPage Today

WASHINGTON — The FDA has approved the first meningococcal vaccine for use in toddlers and infants as young as nine months of age.

The vaccine, called Menactra, is already approved for use in people ages 2 through 55 for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Another meningococcal vaccine, Novartis’s Menveo, also is approved for use in this older group.

Although meningococcal rates are low in the U.S., infants and toddlers are particularly susceptible to the disease, the FDA noted in a press release issued Friday.

Read more….

[Note from SaneVax:  Menactra was FDA approved for use in 2005 for ages 11 to 55. Two years later, the FDA lowered the approved age for those between 2 years old and 55. Now the age is again reduced to cover infants at nine months old receiving their first injection. All for a disease that though dangerous, is ‘relatively rare’ in the United States.

In 2005, when Menactra was originally FDA approved the recommendations for use were to vaccinate at age 11. If not vaccinated previously with Menactra, it was also recommended that adolescents receive this vaccine either prior to entering high school, or prior to entering college. Additional recommendations included various high risk groups such as military personnel and overseas travelers.

In 2007, the recommended age for initial Menactra vaccination was reduced to the age of 2 years. 2010, information was released by the CDC indicating Menactra vaccine efficacy waned after only 5 years. The report above indicates even further age reduction to nine months old. To the average medical consumer, that means according to the CDC booster shots will be required every five or six years to maintain immunity.

At current government vaccine prices, let’s presume the original recommendations issued in 2005 required one booster shot sometime during the patient’s lifetime. That would have made the taxpayer cost for protection against vaccine relevant meningitis approximately $164.00 per person.

With the vaccine efficacy reduced to five years, and the initial vaccination age reduced to nine months the same ‘protection’ would require 11 doses up to the maximum recommended age of 55 years old at a cost of  $903.00 per person. In the six short years since Menactra was approved – the cost for ‘protection’ has increased by approximately $739/per person. That doesn’t sound like much until you multiply it by the approximate population of the United States – 310 million – you will come up with an increase in revenue of approximately $229 billion. Not bad for a product that has been on the market for six years.]

Related

Filed Under: FDA, Meningitis Vaccines, Novartis Tagged With: efficacy, menactra, meningococcal vaccine, recommended administration

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Leixuri from Santurzi

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

hpv vaccine aluminum toxin

HPV vaccine – Aluminum Toxin and Silica Antidote. Grace Filby

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in